<DOC>
	<DOCNO>NCT02318095</DOCNO>
	<brief_summary>This research protocol evaluate feasibility administer neoadjuvant gemcitabine nab-paclitaxel hypofractionated , image guide , intensity modulate radiotherapy ( HIGRT ) resectable borderline resectable pancreatic cancer</brief_summary>
	<brief_title>Gemcitabine/Nab-Paclitaxel With HIGRT Resectable Pancreatic Cancer</brief_title>
	<detailed_description>Pancreatic cancer fourth lead cause cancer-related death United States account roughly 40,000 death year . Despite use neoadjuvant adjuvant therapy , little progress make last three decade , search efficacious treatment continues.In patient good performance status combination effective systemic therapy gemcitabine/nab-paclitaxel high dose local radiotherapy may improve disease outcomes . This prospective , single arm study patient newly diagnose , previously untreated pancreatic cancer plan undergo surgical resection The primary objective study evaluate toxicity neoadjuvant approach incorporate gemcitabine/nab-paclitaxel Hypofractionated image guide intensity-modulated radiotherapy ( HIGRT ) prior surgical resection . Eligible subject recieve standard neoadjuvant gemcitabine nab-paclitaxel dosing follow : Nab-Paclitaxel ( 125mg/m2 ) day 1,8,15 every 28 day 2 cycle Gemcitabine ( 1000mg/m2 ) day 1,8,15 every 28 day 2 cycle follow HIGRT surgical resection . Adjuvant chemotherapy may give post surgery discretion treat medical oncologist .</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>1 . Patient sign informed consent willing comply protocol 2 . Histologically cytologically proven adenocarcinoma pancreas ( within last 90 day ) 3 . Either resectable borderline resectable determine stag imaging ( defined National Comprehensive Cancer Network [ NCCN ] ) 4 . Patient 18 year old 5 . Karnofsky performance status 70 great 6 . The ANC count ≥ 1500 , platelet count ≥ 100,000 hemoglobin ≥ 9g/dL 7 . Laboratory value meet follow constraint : Bilirubin le equal 2 mg/dL ; AST ALT less equal 3 x ULN ( stenting improve biliary obstruction permit ) 8 . No evidence metastatic disease base image chest , abdomen pelvis . 1 . Metastatic disease pretreatment image 2 . Prior systemic therapy 3 . Prior abdominal radiation . Any prior radiation must approve Radiation Oncology PI 4 . Previous treatment pancreatic cancer 5 . Patients serious/poorly control medical psychological condition would exacerbate treatment , would complicate protocol compliance 6 . Pregnant lactating . Adequate birth control must use child bear potential outline protocol . Negative pregnancy test female patient childbearing potential per institutional policy . Postmenopausal woman must amenorrhea least 18 month consider nonchild bear 7 . Clinically significant peripheral vascular disease 8 . Presence active chronic infection 9 . Clinically significant atherosclerotic cardiovascular disease include patient New York Heart Class II/III/IV CHF , ventricular arrhythmia require medication , myocardial infarction , cerebrovascular accident , transient ischemic attack , coronary artery bypass grafting , angioplasty , cardiac vascular stenting within past 6 month 10 . History abdominal fistula , gastrointestinal perforation , intraabdominal abscess within six month prior treatment start 11 . History collagen vascular disease inflammatory bowel disease ( Crohn 's ulcerative colitis ) 12 . Current grade 2 high peripheral neuropathy 13 . Anticoagulation warfarin 14 . History arterial thromboembolic event symptomatic pulmonary embolism within past 6 month 15 . Active bleeding diathesis history major bleeding , CNS bleeding , significant hemoptysis within past 6 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Cancer pancreas</keyword>
</DOC>